Learn More
PURPOSE We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment. (More)
3511 Background: Addition of cetuximab (cet) to first-line chemotherapy (CT) was shown to significantly improve clinical benefit in patients (pts) with KRAS wild-type (wt) mCRC. Pts with KRAS codon(More)
3576 Background: In the CRYSTAL and OPUS studies, adding cetuximab to first-line chemotherapy (CT) improved clinical benefit in patients (pts) with KRAS wild-type (wt) mCRC. R0 resection of(More)